James Moore: Deals look better for the prey than the predator
Outlook AstraZeneca and Yahoo could be corporate twins. They operate in very different sectors but the problems facing both are remarkably similar, and so are the drugs their respective chief executives have settled upon to treat what ails them.
Both are big, wealthy, cash rich, businesses facing flat or declining revenues while struggling to find replacements for products which are losing either patent protection, or relevance, or both.
Both are now hoping that they can buy their way out of their difficulties. That means paying vastly over the odds for companies which have potential but not much beyond that.
Yahoo's recent acquisition of Tumblr, the blogging site which has a popular product but which doesn't make much out of it, is very much in that category.
Meanwhile Astra, which has been doing much the same thing with a string of biotechnology acquisitions, added to its number yesterday with Omthera Pharmaceuticals, whose speciality is fish oil-derived heart medicines.
Its lead drug has at least completed the final stage of its trials, although it still has to secure final US regulatory approvals, but this is hardly new news.
Even after the announcement of the successful trials, the market valued the company at significantly less than Astra paid for it. The purchase price represents an 88 per cent premium to Omthera's Friday close on the Nasdaq.
It's true that heart drugs are a speciality of AstraZeneca and Omthera's product could be combined with the former's cholesterol treatment Crestor. But, as with Yahoo it's very much could, might, if, maybe. And even if the products of their new playthings are winners, both these giants have to prove they can successfully exploit them. Big companies that buy smaller companies, even in industries that put a premium on innovation like the internet or pharmaceuticals, sometimes struggle to do that.
Their shareholders have to hope that their respective spending binges yield a winner or two, because so far the deals they've done look much better for the prey than the predator – prey that could easily be selling snake oil, rather than fish oil, when it comes to making a return for the predator's shareholders.
Malaysia Airlines plane crash exposes alarming flaw in airline security: over one billion flights made last year without stolen-passport check
Kim Jong-un wins 100% of the vote in North Korean elections
Teacher shows sex tape featuring herself to pupils during class by mistake
Malaysia Airlines Flight MH370: Oil slicks in South China Sea ‘not from missing jet’, officials say
Swarm of killer bees sting woman 1,000 times
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
If you're horrified by a flame-roasted dog, you should be shocked at a hog roast
Poor 'live like animals' says Boris's privately educated sister after going on 'poverty safari'
Exclusive: Impact of immigrants on British workers ‘negligible’
Vince Cable: Teachers 'know absolutely nothing' about the world of work
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
- 1 International Women's Day 2014: The shocking statistics that show why it is still so important
- 2 Australian man Rod Sommerville reacts to bite from deadly snake by reaching for cold beer
- 3 Teacher shows sex tape featuring herself to pupils during class by mistake
- 4 David Cameron resorts to paying for Facebook fans because not enough people like him
- 5 Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
iJobs Money & Business
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£55000 - £70000 per annum + benefits: Pro-Recruitment Group: In-House Corporat...
£80000 - £100000 per annum + benefits: Pro-Recruitment Group: In-House Opportu...
£30000 - £35000 per annum + generous benefits: Pro-Recruitment Group: Mixed Ta...